Drug-resistant tuberculosis: Difference between revisions
From IDWiki
m (Aidan moved page Mycobacterium tuberculosis Multi-drug-resistant tuberculosis (MDR-TB) to Multi-drug-resistant tuberculosis without leaving a redirect) |
No edit summary |
||
| Line 1: | Line 1: | ||
| ⚫ | |||
= Multi-drug-resistant tuberculosis (MDR-TB) = |
|||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
* 8 months of an intensive four-drug regimen that includes any four drugs to which it is susceptible, in order of preference: |
* 8 months of an intensive four-drug regimen that includes any four drugs to which it is susceptible, in order of preference: |
||
| Line 13: | Line 11: | ||
** Other second-line agents, starting with ethionamide |
** Other second-line agents, starting with ethionamide |
||
* Followed by 12 months of a less intensive regimen (at least three effective drugs), for a total of at least 20 months |
* Followed by 12 months of a less intensive regimen (at least three effective drugs), for a total of at least 20 months |
||
[[Category:TB]] |
|||
Revision as of 03:24, 15 August 2019
Definition
- Tuberculosis infection that is resistant to both first-line drugs, isoniazid and rifampin
Management
- 8 months of an intensive four-drug regimen that includes any four drugs to which it is susceptible, in order of preference:
- Any first-line agents to which it is still susceptible
- A fluoroquinolone (except ciprofloxacin)
- An injectable: kanamycin, or other parenteral agent
- Other second-line agents, starting with ethionamide
- Followed by 12 months of a less intensive regimen (at least three effective drugs), for a total of at least 20 months
References
- ^ Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis, Ilaria Motta, Nargiza Parpieva, Zinaida Tigay, Varvara Solodovnikova, Irina Liverko, Ronelle Moodliar, Matthew Dodd, Nosipho Ngubane, Mohammed Rassool, Timothy D. McHugh, Melvin Spigelman, David A.J. Moore, Koert Ritmeijer, Philipp du Cros, Katherine Fielding. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. New England Journal of Medicine. 2022;387(25):2331-2343. doi:10.1056/nejmoa2117166.
